MnA round-up: AAA bags Atreus; Pulmonx acquires Aeris
This article was originally published in Clinica
Executive Summary
Medtech M&A activity shows no sign of slowing down in the New Year, with two more deals. French nuclear imaging firm Advanced Accelerator Applications (AAA) has bought the remaining 49.9% stake in Canada’s Atreus Pharmaceuticals; while Pulmonx, a specialist in minimally-invasive treatments for pulmonary disorders, has acquired the assets of Aeris Therapeutics, including its AeriSeal foam-based lung sealant system for the treatment of emphysema.
You may also be interested in...
Pulmonx Reaches Multiple Milestones In Lung-Valve, Diagnostics Development
Encouraging results from the IMPACT study of Pulmonx's Zephyr endobronchial valve in patients with homogenous emphysema – a population with almost no other options – is the latest in string of good news for the Silicon Valley company, which wants to create a new paradigm of personalized device therapy for pulmonary disease.
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.